Atara Biotherapeutics Inc ATRA 深 滬
已收盤 11-06 16:00:00 美东时间
7.87
-0.090
-1.13%
華盛通- 最 高8.00
- 今 開7.86
- 成交量 1.63万股
- 最 低 7.74
- 昨 收 7.96
- 總市值 7.90万
- 52周最高 19.145
- 市盈率 靜 3.06
- 換手率 0.16%
- 52周最低 3.92
- 委 比 36.49%
- 總股本 1.00万
- 歷史最高 65.56
- 量 比 0.69
- 振 幅 3.27%
- 歷史最低 0.1986
- 每 手 1
- 風險率 3.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atara Biotherapeutics收涨5.87%，成交额26.53万美元
11月3日，Atara Biotherapeutics（ATRA）收涨5.87%，报8.48美元，成交额26.53万美元，市值8511.97万美元。 行情数据...
11-03 08:05
Atara Biotherapeutics收跌8.91%，成交额21.68万美元
10月24日，Atara Biotherapeutics（ATRA）收跌8.91%，报8.59美元，成交额21.68万美元，市值8622.39万美元。 行情数据...
10-24 07:10
Atara Biotherapeutics收跌4.87%，成交额18.57万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:10
美股夜盘 | Atara Biotherapeutics Inc暴泻15.79%，最新股价8.05美元
Atara Biotherapeutics Inc暴泻15.79%，报8.05美元
10-15 10:31
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals,...
10-14 20:08
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre Pharmac...
09-30 20:09
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer effective August 17, 2026. Dr. Joshi brings over two decades of leadership experience in drug development, regulatory processes, and lifecycle management. His expertise will support Rhythm’s advancements in next-generation MC4R agonists and its leadership in rare neuroendocrine diseases. Previously, Dr. Joshi served as Chief Development Officer a...
08-17 12:00
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $630.000 thousand which beat the ana...
08-13 04:25
Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
05-13 05:31
Atara Biotherapeutics Files Prospectus For Offering $79.3M Common Shares
https://www.sec.gov/Archives/edgar/data/1604464/000119312526219518/atra-424-b5-2026_q2.htm
05-13 04:58
